TP53 and exocrine pancreatic carcinoma: As can be seen from Fig. 8F and Additional file 3: Figure S3F, more mutated genes were detected in arterial CTCs than tissues and venous CTCs in patients with pancreatic carcinoma, and the mutated genes targeted with clinically available drugs (TP53, NRAS) were detected in arterial CTCs.